Skip to main content
. 2023 Sep 25;12(19):19794–19806. doi: 10.1002/cam4.6544

FIGURE 3.

FIGURE 3

Subgroup analysis between ctDNA detection and recurrence in cancer patients treated with neoadjuvant treatment. (A) Subgroup analysis of cancer type. (B) Subgroup analysis of ctDNA detection time point. (C) Subgroup analysis of various area. CI, confidential interval; GI tract, gastrointestinal tract; NAT, neoadjuvant treatment; Random, random‐effects model.